ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1130

Chronic Risk Factors for Recurrent Gout Flares Among Established Gout Patients: A Prospective Cohort Analysis

Yuqing Zhang1, Jie Wei2, Chio Yokose2, Sharan K. Rai3,4 and Hyon K. Choi2, 1Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, 2Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, 3Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, 4Graduate School of Arts and Sciences, Harvard University, Cambridge, MA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Co-morbidities, Epidemiologic methods, Gout and uric acid

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: Epidemiology and Public Health Poster II: Gout, Ankylosing Spondylitis, Osteoarthritis, Osteoporosis, Pain, and Function

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Understanding the risk factors for recurrent flares among established gout patients is directly relevant to clinical care; however, relevant data are scarce. A previous prospective study of 197 gout patients found that chronic risk factors such as age, sex, education level, obesity, gout disease duration, and the presence of hypertension, diabetes, renal disease, or congestive heart failure (CHF) were not significantly associated with the risk of recurrent gout, although some point estimates were suggestive of an association. We re-examined the same risk factors among 997 gout patients in an expanded follow-up study.

Methods: We conducted a cohort analysis of a prospective study designed to examine the associations of putative risk factors with recurrent gout attacks. Individuals with gout were recruited and followed up online for one year. Participants were asked to provide the following information regarding their gout attacks: date of gout attack onset, symptoms and signs, medications (including anti-gout medications), and exposure to potential risk factors at baseline and during the follow-up in relation to gout flares. We used Cox proportional hazard models to calculate hazard ratios for the risk of recurrent gout attacks related to age, sex, education level, body mass index, gout disease duration, and the presence of hypertension, diabetes, renal disease, and CHF at baseline.

Results: Among 997 gout patients (mean age, 53.6 years; 78.4% male), we documented 361 gout flares during a mean follow-up of 0.49 years. Overall, the annual incidence rate was 75 per 100 person-years (Table). Younger age (<60 years), disease duration (>1 year), and the presence of CHF were independently associated with a 45%, 71%, and 57% higher risk of gout flares, respectively (Table). Female sex, obesity, and diabetes tended to be associated with a higher risk of gout flares (Table), although not statistically significant.

Conclusion: This large prospective gout cohort study suggests that younger age, longer disease duration, and having CHF all confer a higher risk of gout flares, independent of other risk factors. While these associations may be due to higher serum urate levels and pools associated with these factors even among gout patients, it remains conceivable that these factors may contribute to the risk of flares independent of their urate level impact. Regardless, these data suggest a potential need for more aggressive therapy among patients with these risk factors.

Risk Factor

No. of Gout Flares

Incidence Rate

(per 100 person-years)

Age-, Sex-Adjusted

RR (95% CI)

Multivariable

RR (95% CI)*

All

361

74.6

–

–

Age

≥60 years

113

61.8

1.0

1.0

<60 years

248

82.4

1.39 (1.11, 1.74)

1.45 (1.14, 1.85)

Sex

Female

86

86.1

1.0

1.0

Male

275

71.6

0.80 (0.62, 1.02)

0.78 (0.61, 1.01)

Education

<College graduate

161

82.9

1.0

1.0

College graduate

200

69.4

0.86 (0.70, 1.06)

0.94 (0.76, 1.17)

Body Mass Index (kg/m2)

<25

31

56.6

1.0

1.0

25-29.9

124

67.7

1.21 (0.81, 1.79)

1.23 (0.83, 1.82)

≥30

206

83.9

1.46 (1.00, 2.13)

1.40 (0.96, 2.05)

Disease Duration

<1 year

47

48.8

1.0

1.0

≥1 year

314

81.0

1.73 (1.26, 2.36)

1.71 (1.25, 2.33)

Presence of DM

No

305

71.4

1.0

1.0

Yes

56

99.5

1.53 (1.15, 2.05)

1.32 (0.97, 1.80)

Presence of CHF

No

333

72.4

1.0

1.0

Yes

28

117.2

1.86 (1.26, 2.75)

1.57 (1.05, 2.36)

Presence of CKD

No

306

73.5

1.0

1.0

Yes

55

81.9

1.19 (0.89, 1.60)

1.14 (0.84, 1.54)

Presence of HTN

No

223

73.0

1.0

1.0

Yes

138

77.5

1.17 (0.94, 1.47)

1.05 (0.83, 1.33)

CHF = congestive heart failure, CKD = chronic kidney disease, DM = diabetes mellitus, HTN = hypertension.

*Mutually adjusted for the variables in this table.


Disclosure: Y. Zhang, None; J. Wei, None; C. Yokose, None; S. K. Rai, None; H. K. Choi, Takeda, Selecta, Kowa, and Horizon, 5,Selecta and Horizon, 2.

To cite this abstract in AMA style:

Zhang Y, Wei J, Yokose C, Rai SK, Choi HK. Chronic Risk Factors for Recurrent Gout Flares Among Established Gout Patients: A Prospective Cohort Analysis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/chronic-risk-factors-for-recurrent-gout-flares-among-established-gout-patients-a-prospective-cohort-analysis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/chronic-risk-factors-for-recurrent-gout-flares-among-established-gout-patients-a-prospective-cohort-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology